

Published in final edited form as:

*Biochim Biophys Acta*. 2012 May ; 1822(5): 685–689. doi:10.1016/j.bbadis.2011.09.020.

## Antioxidants in the Canine Model of Human Aging

Amy L.S. Dowling, PhD and Elizabeth Head, PhD.

Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40536

### Abstract

Oxidative damage can lead to neuronal dysfunction in the brain due to modifications to proteins, lipids and DNA/RNA. In both human and canine brain, oxidative damage progressively increases with age. In the Alzheimer's disease (AD) brain, oxidative damage is further exacerbated, possibly due to increased deposition of beta-amyloid (A $\beta$ ) peptide in senile plaques. These observations have led to the hypothesis that antioxidants may be beneficial for brain aging and AD. Aged dogs naturally develop AD-like neuropathology (A $\beta$ ) and cognitive dysfunction and are a useful animal model in which to test antioxidants. In a longitudinal study of aging beagles, a diet rich in antioxidants improved cognition, maintained cognition and reduced oxidative damage and A $\beta$  pathology in treated animals. These data suggest that antioxidants may be beneficial for human brain aging and for AD, particularly as a preventative intervention.

### Keywords

Alzheimer disease; beagle; beta-amyloid; cognition; dog; lipoic acid; vitamins

### 1.1 Introduction

Progressive oxidative damage is a consistent feature of aging [1–4]. The brain is particularly vulnerable to oxidative damage, as it consumes approximately 20% of the body's total oxygen, has a high content of polyunsaturated fatty acids and has lower levels of endogenous antioxidant activity relative to other tissue [5–7]. Normal metabolic processes result in the release of reactive oxygen species (ROS), which in turn can lead to oxidative damage to proteins, lipids, DNA and RNA [1]. ROS are produced primarily from mitochondria [8], intracellular organelles that are themselves vulnerable to oxidative damage [9]. The combination of mitochondrial dysfunction and production of ROS may be a key contributor to the deleterious effects of aging on the brain [10–18].

Studies of normal human brain aging provide correlative evidence suggesting that oxidative damage plays a role in age-associated cognitive losses. Studies of human autopsy tissue show higher levels of oxidative damage to nucleic acids [19–21], proteins [20, 22–25] and lipids [21, 25, 26] in aged brain as compared to young brain. Mitochondrial function also appears compromised with age in the human brain [3, 4, 14, 27]. In normal aging, mitochondrial respiratory chain activity declines [28], mitochondrial metabolism-associated

© 2011 Elsevier B.V. All rights reserved.

Corresponding Author: Elizabeth Head, Ph.D., Associate Professor, University of Kentucky, Sanders-Brown Center on Aging, Department of Molecular and Biomedical Pharmacology, 203 Sanders-Brown Building, 800 South Limestone Street, Lexington, KY, 40536, Phone: 859-257-1412 ext 481, Fax: 859-323-2866.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

enzymes such as aconitase decrease [29] and the rate of somatic mitochondrial DNA mutations increases [17, 30]. Thus, mitochondrial dysfunction and the production of ROS, combined with lower endogenous antioxidant activity, may lead to increasing oxidative damage to molecules critically important to neuronal function.

## 1.2 Oxidative Stress and Alzheimer's Disease

Oxidative damage may also play a role in age-associated neurodegenerative diseases such as Alzheimer's disease (AD) [31–33]. AD is a progressive neurodegenerative disease that causes dementia in the elderly. AD is characterized by the accumulation of beta-amyloid (A $\beta$ ) in extracellular senile plaques and intracellular hyperphosphorylated tau protein in neurofibrillary tangles [34]. Consequently, extensive neuron loss is observed in the AD brain in the cortex and particularly within the hippocampus, a region of the brain involved with memory. AD is associated with further increases in oxidative damage to protein [20, 23, 24, 35–42], lipid [21, 26, 43–46], DNA [47–49] and RNA [12, 50, 51] relative to elderly controls. In addition, endogenous antioxidant activity in the AD brain is reduced relative to age-matched controls [20, 25, 52]. Proteins particularly vulnerable to oxidative damage have been identified by proteomics, with a subset of these proteins putatively involved directly or indirectly in the production and accumulation of AD neuropathology [53]. Mitochondrial dysfunction also occurs in AD, with decreased respiratory chain activity [15, 54, 55] and increased mitochondrial DNA mutations [56] observed at higher rates when compared to age-matched controls. Further, decreased cytochrome oxidase activity in the posterior cingulate cortex of AD patients is correlated with hypometabolism seen by positron emission studies [57]. A gene array study in the cingulate cortex shows that energy-metabolism related genes decrease in AD, with a 65% reduction in expression of mitochondrial electron transport chain genes [58].

Based on correlative human neuropathology studies, antioxidants are predictive of healthy aging, may reduce the risk of developing AD and may improve cognitive function in AD patients. However, studies in humans have shown either a positive effect of antioxidant use on cognition and risk reduction for developing AD [59–61] or no significant effects [62–65]. Few systematic and controlled clinical trials have evaluated the effects of antioxidants on cognition in aged individuals or patients with AD. Intake of vitamin E delays institutionalization in AD patients [66], suggesting some beneficial effects. However, vitamin E alone did not improve cognition in patients with mild cognitive impairment, which is thought to precede AD [67]. Further, in non-demented elderly women, vitamin E treatment was associated with little improvement in cognition [64].

In addition to investigating the effects of cellular antioxidants on cognition and risk of AD, several studies examined the effects of targeted co-factors that improve mitochondrial function, including acetylcarnitine (ALCAR) and lipoic acid (LA). ALCAR and LA may improve mitochondrial function and reduce the production of ROS, thus also reducing oxidative damage to proteins, lipids and DNA/RNA [68]. In studies where ALCAR was administered to patients with moderate to severe AD, either improved cognition and/or slower deterioration was observed [69–72]. In early-onset AD patients (less than 65 years of age), only small cognitive improvements were noted [73], although younger patients with AD (less than 61 years) may also have experienced slowed disease progression [74, 75]. When the results of all these studies are combined in a meta-analysis, ALCAR administration in patients with AD was clearly beneficial, particularly with respect to slowing cognitive decline [76]. Further, combining ALCAR with acetylcholinesterase therapy in AD may provide additional benefits [77]. Similar evidence of maintenance of function was observed in an open label study of 9 patients with AD or related dementias receiving 600 mg/day of LA for an average of 337 days [78]. In a larger follow up study of

48 patients for a 48 month treatment period, maintenance of function was also observed [79].

Taken together, studies of dietary or supplemental antioxidant intake in humans reveal variable results and appear far less robustly associated with positive functional outcomes than those reported in the rodent aging literature [9, 18, 80–87]. Variability in the outcomes of human antioxidant clinical trials outcomes may reflect inconsistencies in the amount of supplements provided, their form and source (e.g. lower AD brain neuropathology is associated with cerebrospinal fluid levels of alpha-tocopherol and not gamma-tocopherol [88]), their duration and regularity of use and challenges in determining the exact background of dietary antioxidants [89]. Interestingly, combinations of antioxidants may be superior to single compound supplementation [90] and dietary intake of antioxidants is superior to supplements in human studies on cognition and risk of developing AD [91, 92]. Further, supplementation of elderly women with a combination of vitamins E and C can lead to improved memory [93]. Thus, antioxidants may prove to be more efficacious if administered in combination with other antioxidants (e.g. vitamin C, which helps to recycle Vitamin E) and through diet, rather than as a supplement.

A panel of experts for the Duke Evidence-based Practice Center for the US Department of Health and Human Services recently reviewed the literature and, not surprisingly, reported no consistent or robust evidence to suggest that single or dual antioxidant use is protective against AD [94]. In terms of preventing cognitive decline with aging, vegetable intake was only weakly associated with decreased risk of developing AD, whereas cognitive training was strongly associated with decreased risk. Thus, the role of either dietary or supplemental antioxidants and level of protection against cognitive decline or AD has yet to be clearly established. Additional reasons for the small or negative effects of antioxidants on cognition in the elderly and for treatment of AD [80, 95] include the limitations of animal models (primarily rodent) in terms of ability to predict human response. Therefore, it is useful to consider other animal models of human aging and AD, and also to test the potential for combinations of antioxidants/ mitochondrial co-factors to improve cognition and reduce A $\beta$ . Specifically, dogs are frequently used to evaluate safety of drugs and in food metabolism studies given their substantial similarities to humans.

### 1.3 Studies in Aged Dogs

Dogs may be particularly useful in studying human brain aging because they naturally develop cognitive decline with age, accumulate oxidative damage and A $\beta$  protein [96]. In dog brain, oxidative damage to proteins increases with age [97, 98] and is associated with reduced endogenous antioxidant enzyme activity or protein levels [97, 99–101]. In several studies, a relation between age and increased oxidative damage has been inferred by measuring the amount of end products of lipid peroxidation to predict oxidative damage to lipids. These end products including 4-hydroxynonenal [101–104] and malondialdehyde [97]. Additionally, we and others have reported evidence of increased oxidative damage to DNA or RNA (8OHdG) in aged dog brain [96, 104].

Oxidative damage may also be associated with behavioral decline in dogs. Rofina and collaborators examined oxidative end products (lipofuscin-like pigment and protein carbonyls) in aged companion dog brain [98, 103, 104] and found a correlation between increased oxidative end products and severity of behavior changes due to cognitive dysfunction. Similarly, in our own studies of aging beagles, higher protein oxidative damage (3-nitrotyrosine) and lower endogenous antioxidant capacity (superoxide dismutase and glutathione-S-transferase) are associated with poorer prefrontal-dependent and spatial learning [100]. These correlative studies suggest a link between cognition and progressive

oxidative damage in the dog, suggesting their utility in testing antioxidant treatment strategies.

To test the hypothesis that reduced oxidative stress leads to cognitive benefits, we implemented a longitudinal study of aged dogs. In this study, a combination of antioxidants and mitochondrial co-factors was provided in food [105–109]. 48 aged beagles (between ~8–12 years) were divided into four groups that were balanced with respect to baseline cognitive ability, sex and age: (1) no behavioral enrichment/control diet group; (2) behavioral enrichment/control diet; (3) no behavioral enrichment/antioxidant diet; and (4) combined behavioral enrichment and antioxidant diet. In a subset of experiments, an additional 17 young beagles (<5 years of age) were included for comparison to aged dogs. Young dogs were all placed in the behavioral enrichment condition, with half provided with the antioxidant diet (i.e. similar to groups 2 and 4).

Three unique features of the experiment included: 1) a combination of antioxidants and mitochondrial co-factors; 2) incorporation of all antioxidants and mitochondrial co-factors into food and; 3) evaluation of dietary treatments in combination with behavioral enrichment. An antioxidant-enriched dog diet was formulated to include a broad spectrum of antioxidants and two mitochondrial co-factors [108]. Based on an average weight of 10 kg per animal, the daily doses for each compound were 800 IU or 210 mg/day (21 mg/kg/day) of vitamin E, 16 mg/day (1.6 mg/kg/day) of vitamin C, 52 mg/day (5.2 mg/kg/day) of carnitine and 26 mg/day (2.6 mg/kg/day) of lipoic acid. Fruits and vegetables were also incorporated at a 1 to 1 exchange ratio for corn, resulting in 1% inclusions (dehydrated) of each of the following: spinach flakes, tomato pomace, grape pomace, carrot granules and citrus pulp. This was equivalent to raising fruits and vegetable intake from 3 servings per day to 5–6 servings per day based upon ORAC values [110]. Additionally, vitamin E was increased by ~75% in dogs treated with the antioxidant diet [111]. The behavioral enrichment condition consisted of additional cognitive experience (20–30 min/day, 5 days/week), an enriched sensory environment (housing with a kennel-mate, weekly rotation of play toys in kennel) and physical exercise (two 20 min outdoor walks/week) [108].

Dogs were evaluated over a 2.8 year period to evaluate short term and chronic treatment effects. Treatment with the antioxidant diet lead to cognitive improvements in learning within two weeks, with aged animals showing significant improvements in spatial attention (landmark task) [111]. Subsequent testing of animals with a more difficult complex learning task (odddity discrimination) also revealed benefits of the diet [105]. With antioxidant treatment, visual discrimination improved and reversal (frontal function) learning ability was maintained over time while untreated animals showed a progressive decline [108]. This was despite the fact that for each time point where discrimination learning was re-administered, the task was made more difficult (harder to distinguish objects) to prevent a practice effect. Thus the progressive increase in error scores over time in untreated dogs reflects both increased task difficulty and possibly, longitudinal aging effects. Interestingly, the dogs fed an antioxidant diet benefited from behavioral enrichment, in that cognitive scores of aged dogs receiving both treatments were superior to either treatment alone [107, 108]. For example, in singly treated animals spatial memory showed a trend toward improvement, reaching statistical significance only after long-term treatment (>2 years) with a combination of both the antioxidant diet and behavioral enrichment [109]. The antioxidant diet selectively repaired an aging deficit, in that cognitive scores from young dogs treated with the antioxidant diet did not differ from those of young dogs fed control diet [112].

Neurobiological studies showed reduced oxidative damage and increased endogenous antioxidant activity in antioxidant-fed dogs, particularly among animals receiving the combination of antioxidants and behavioral enrichment [100]. Interestingly, the antioxidant

diet increased the levels of glutathione suggesting a possible involvement of a possible vitagene network that might account for the increased expression of antioxidant molecules and growth proteins [113, 114]. Given that the diet provided to the dogs also included acetylcarnitine, resulting in increased levels of HO-1 also support the possibility that vitagene networks are engaged [113].

Mitochondrial function was significantly improved in the antioxidant fed dogs and not in behaviorally enriched dogs [115]. Interestingly, behavioral enrichment but not the antioxidant diet protected against neuron loss in the hilus of the dog hippocampus [116]. Further, brain derived neurotrophic factor mRNA increased in aged dogs provided with the combination treatment [117]. These results suggest that cognitive benefits of antioxidants can be further enhanced with the addition of behavioral enrichment, perhaps due to different yet synergistic mechanisms of action in the brain, including reduced oxidative damage and maintenance of neuron health. In addition to brain, however, peripheral benefits were also seen, including less cellular degeneration in the inner ear [118].

Interestingly, in a recent study of aged dogs, the formulation of the diet was modified to compare only the mitochondrial co-factors used in this previous study and effects on cognition [119]. Aged dogs were treated with lipoic acid, ALCAR or the combination and tested with spatial learning and discrimination/reversal tasks. When these compounds were included with a broader spectrum of antioxidants described above, no cognitive benefits were observed when evaluated singly or in combination. Additionally, protein carbonyl accumulation in the plasma of treated dogs was increased. Increased oxidative damage may reflect either higher doses of the mitochondrial co-factors used in this study or increased oxidative stress resulting from not counterbalancing mitochondrial cofactors with cellular antioxidants. Consistent with this explanation, another smaller study demonstrated improved short term memory in aged beagles treated with a combination of phosphatidylserine, Ginkgo biloba, vitamin E and pyridoxine [120].

## 1.4 Summary

Using the canine model of aging, we show that providing a broad spectrum of cellular antioxidants and mitochondrial co-factors within a specially-formulated food leads to significant benefits to cognition and maintenance of function at doses that were well within those used in human clinical trials. In addition, combining an antioxidant enriched diet with cognitive training, physical exercise and social enrichment provides additional benefits to cognition. Future studies in humans may be more efficacious if combinations of antioxidants are evaluated in parallel with additional lifestyle improvements (e.g. social engagement, cognitive training and physical exercise)

## Acknowledgments

The antioxidant study in aged canines was supported by funding from the NIH/NIA AG12694.

## References

1. Poon HF, Calabrese V, Scapagnini G, Butterfield DA. Free radicals and brain aging. *Clin Geriatr Med.* 2004; 20:329–359. [PubMed: 15182885]
2. Liu J, Mori A. Stress, aging and brain oxidative damage. *Neurochem Res.* 1999; 24:1479–1497. [PubMed: 10555789]
3. Ames BN, Shigenaga MK. Oxidants are a major contributor to aging. *Annals of the New York Academy of Sciences.* 1992; 663:85–96. [PubMed: 1482105]
4. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. *Proc Natl Acad Sci USA.* 1993; 90:7915–7922. [PubMed: 8367443]

5. Shulman RG, Rothman DL, Behar KL, Hyder F. Energetic basis of brain activity: implications for neuroimaging. *Trends Neurosci.* 2004; 27:489–495. [PubMed: 15271497]
6. Halliwell B, Gutteridge JMC. Oxygen radicals in the nervous system. *Trends in Neuroscience.* 1985; 8:22–26.
7. Floyd RA, Hensley K. Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. *Neurobiol Aging.* 2002; 23:795–807. [PubMed: 12392783]
8. Perez-Campo R, Lopez-Torres M, Cadenas S, Rojas C, Barja G. The rate of free radical production as a determinant of the rate of aging: evidence from the comparative approach. *J Comp Physiol [B].* 1998; 168:149–158.
9. Liu J, Atamna H, Kuratsune H, Ames BN. Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites. *Ann N Y Acad Sci.* 2002; 959:133–166. [PubMed: 11976193]
10. Mori A, Utsumi K, Liu J, Hosokawa M. Oxidative damage in the senescence-accelerated mouse. *Ann N Y Acad Sci.* 1998; 854:239–250. [PubMed: 9928434]
11. Nakahara H, Kanno T, Inai Y, Utsumi K, Hiramatsu M, Mori A, Packer L. Mitochondrial dysfunction in the senescence accelerated mouse (SAM). *Free Radic Biol Med.* 1998; 24:85–92. [PubMed: 9436617]
12. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. *Ann Neurol.* 1994; 36:747–751. [PubMed: 7979220]
13. Wei YH. Oxidative stress and mitochondrial DNA mutations in human aging. *Proceedings of the Society for Experimental Biology and Medicine.* 1998; 217:53–63. [PubMed: 9421207]
14. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. *Proc Natl Acad Sci USA.* 1994; 91:10771–10778. [PubMed: 7971961]
15. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, Smith MA. Mitochondrial abnormalities in Alzheimer's disease. *J Neurosci.* 2001; 21:3017–3023. [PubMed: 11312286]
16. Miquel J, Economos AC, Fleming J, Johnson JE Jr. Mitochondrial role in cell aging. *Experimental Gerontology.* 1980; 15:575–591. [PubMed: 7009178]
17. Wallace DC. Mitochondrial genetics: a paradigm for aging and degenerative diseases? *Science.* 1992; 256:628–632. [PubMed: 1533953]
18. Haripriya D, Devi MA, Kokilavani V, Sangeetha P, Panneerselvam C. Age-dependent alterations in mitochondrial enzymes in cortex, striatum and hippocampus of rat brain -- potential role of L-Carnitine. *Biogerontology.* 2004; 5:355–364. [PubMed: 15547323]
19. Mecocci P, MacGarvey U, Kaufman AE, Koontz D, Shoffner JM, Wallace DC, Beal MF. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. *Ann Neurol.* 1993; 34:609–616. [PubMed: 8215249]
20. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. *Proc Natl Acad Sci U S A.* 1991; 88:10540–10543. [PubMed: 1683703]
21. Montine TJ, Neely MD, Quinn JF, Beal MF, Markesbery WR, Roberts LJ, Morrow JD. Lipid peroxidation in aging brain and Alzheimer's disease. *Free Radical Biology & Medicine.* 2002; 33:620–626. [PubMed: 12208348]
22. Stadtman ER. Protein oxidation and aging. *Science.* 1992; 257:1220–1224. [PubMed: 1355616]
23. Stadtman ER, Berlett BS. Reactive oxygen-mediated protein oxidation in aging and disease. *Chem Res Toxicol.* 1997; 10:485–494. [PubMed: 9168245]
24. Berlett BS, Stadtman ER. Protein oxidation in aging disease, and oxidative stress. *JBC.* 1997; 272:20313–20316.
25. Cini M, Moretti A. Studies on lipid peroxidation and protein oxidation in the aging brain. *Neurobiology of Aging.* 1995; 16:53–57. [PubMed: 7723936]
26. Markesbery WR, Lovell MA. Four-hydroxynonenal a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. *Neurobiol Aging.* 1998; 19:33–36. [PubMed: 9562500]

27. Cassarino DS, Bennett JP Jr. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations, oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. *Brain Res Brain Res Rev.* 1999; 29:1–25. [PubMed: 9974149]
28. Ojaimi J, Masters CL, Opeskin K, McKelvie P, Byrne E. Mitochondrial respiratory chain activity in the human brain as a function of age. *Mech Ageing Dev.* 1999; 111:39–47. [PubMed: 10576606]
29. Yan L-J, Levine RL, Sohal RS. Oxidative damage during aging targets mitochondrial aconitase. *Proc Natl Acad Sci, USA.* 1997; 94:11168–11172. [PubMed: 9326580]
30. Michikawa Y, Mazzucchelli F, Bresolin N, Scarlato G, Attardi G. Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. *Science.* 1999; 286:774–779. [PubMed: 10531063]
31. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. *Free Radic Biol Med.* 1997; 23:134–147. [PubMed: 9165306]
32. Pratico D, Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. *Am J Med.* 2000; 109:577–585. [PubMed: 11063960]
33. Behl C. Alzheimer's disease and oxidative stress: Implications for novel therapeutic approaches. *Progress in Neurobiology.* 1999; 57:301–323. [PubMed: 10096843]
34. Mirra SS. The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. *Neurobiol Aging.* 1997; 18:S91–94. [PubMed: 9330994]
35. Butterfield DA, Kanski J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. *Mech Ageing Dev.* 2001; 122:945–962. [PubMed: 11348660]
36. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. *J Neurosci.* 1997; 17:2653–2657. [PubMed: 9092586]
37. Su JH, Deng G, Cotman CW. Neuronal DNA damage precedes tangle formation and is associated with up-regulation of nitrotyrosine in Alzheimer's Disease brain. *Brain Research.* 1997; 774:193–199. [PubMed: 9452208]
38. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita SP, Wu JF, Carney JM, Lovell M, Markesbery WR, Butterfield DA. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. *J Neurochem.* 1995; 65:2146–2156. [PubMed: 7595501]
39. Lyras L, Cairns NJ, Jenner A, Jenner P, Halliwell B. An assessment of oxidative damage to proteins, lipids and DNA in brain from patients with Alzheimer's disease. *Journal of Neurochemistry.* 1997; 68:2061–2069. [PubMed: 9109533]
40. Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR. Protein oxidation in the brain in Alzheimer's disease. *Neuroscience.* 2001; 103:373–383. [PubMed: 11246152]
41. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. *Free Radic Biol Med.* 2002; 33:562–571. [PubMed: 12160938]
42. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. *J Neurochem.* 2002; 82:1524–1532. [PubMed: 12354300]
43. Palmer AM, Burns MA. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. *Brain Research.* 1994; 645:338–342. [PubMed: 8062096]
44. Sayre LM, Zelasko DA, Harris PLR, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. *Journal of Neurochemistry.* 1997; 68:2092–2097. [PubMed: 9109537]
45. Pratico D, Lee MY, Trojanowski JQ, Rokach J, Fitzgerald GA. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. *Faseb Journal.* 1998; 12:1777–1783. [PubMed: 9837868]

46. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA. Increased 8,12-iso-iPF<sub>2</sub>alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. *Ann Neurol.* 2000; 48:809–812. [PubMed: 11079549]
47. Lovell MA, Markesbery WR. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. *Nucleic Acids Res.* 2007; 35:7497–7504. [PubMed: 17947327]
48. Lovell MA, Gabbita SP, Markesbery WR. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. *Journal of Neurochemistry.* 1999; 72:771–776. [PubMed: 9930752]
49. Gabbita SP, Lovell MA, Markesbery WR. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. *Journal of Neurochemistry.* 1998; 71:2034–2040. [PubMed: 9798928]
50. Lovell MA, Markesbery WR. Oxidatively modified RNA in mild cognitive impairment. *Neurobiol Dis.* 2008; 29:169–175. [PubMed: 17920285]
51. Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, Smith MA. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. *The Journal of Neuroscience.* 1999; 19:1959–1964. [PubMed: 10066249]
52. Pappolla MA, Omar RA, Kim KS, Robakis NK. Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. *Am J Pathol.* 1992; 140:621–628. [PubMed: 1372157]
53. Butterfield DA. Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. *Brain Res.* 2004; 1000:1–7. [PubMed: 15053946]
54. Gibson GE, Sheu KF, Blass JP. Abnormalities of mitochondrial enzymes in Alzheimer disease. *J Neural Transm.* 1998; 105:855–870. [PubMed: 9869323]
55. Bosetti F, Brizzi F, Barogi S, Mancuso M, Siciliano G, Tendi EA, Murri L, Rapoport SI, Solaini G. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. *Neurobiol Aging.* 2002; 23:371–376. [PubMed: 11959398]
56. Coskun PE, Beal MF, Wallace DC. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. *Proc Natl Acad Sci U S A.* 2004; 101:10726–10731. [PubMed: 15247418]
57. Valla J, Berndt JD, Gonzalez-Lima F. Energy hypometabolism in posterior cingulate cortex of Alzheimer's patients: superficial laminar cytochrome oxidase associated with disease duration. *J Neurosci.* 2001; 21:4923–4930. [PubMed: 11425920]
58. Liang WS, Reiman EM, Valla J, Dunckley T, Beach TG, Grover A, Niedzielko TL, Schneider LE, Mastroeni D, Caselli R, Kukull W, Morris JC, Hulette CM, Schmechel D, Rogers J, Stephan DA. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. *Proc Natl Acad Sci U S A.* 2008; 105:4441–4446. [PubMed: 18332434]
59. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, Breteler MM. Dietary intake of antioxidants and risk of Alzheimer disease. *JAMA.* 2002; 287:3223–3229. [PubMed: 12076218]
60. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS. Vitamin E and cognitive decline in older persons. *Arch Neurol.* 2002; 59:1125–1132. [PubMed: 12117360]
61. Maxwell CJ, Hicks MS, Hogan DB, Basran J, Eby EM. Supplemental use of antioxidant vitamins and subsequent risk of cognitive decline and dementia. *Dement Geriatr Cogn Disord.* 2005; 20:45–51. [PubMed: 15832036]
62. Luchsinger JA, Tang MX, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. *Arch Neurol.* 2003; 60:203–208. [PubMed: 12580704]
63. Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, Havlik R, White LR. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. *Neurology.* 2000; 54:1265–1272. [PubMed: 10746596]
64. Kang JH, Cook N, Manson J, Buring JE, Grodstein F. A randomized trial of vitamin E supplementation and cognitive function in women. *Arch Intern Med.* 2006; 166:2462–2468. [PubMed: 17159011]
65. Fillenbaum GG, Kuchibhatla MN, Hanlon JT, Artz MB, Pieper CF, Schmader KE, Dysken MW, Gray SL. Dementia and Alzheimer's disease in community-dwelling elders taking vitamin C and/or vitamin E. *Ann Pharmacother.* 2005; 39:2009–2014. [PubMed: 16227448]



66. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. *The New England Journal of Medicine*. 1997; 336:1216–1222. [PubMed: 9110909]
67. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ. Vitamin E and donepezil for the treatment of mild cognitive impairment. *N Engl J Med*. 2005; 352:2379–2388. [PubMed: 15829527]
68. Liu J, Killilea DW, Ames BN. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L- carnitine and/or R-alpha -lipoic acid. *Proc Natl Acad Sci U S A*. 2002; 99:1876–1881. [PubMed: 11854488]
69. Rai G, Wright G, Scott L, Beston B, Rest J, Exton-Smith AN. Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia. *Curr Med Res Opin*. 1990; 11:638–647. [PubMed: 2178869]
70. Pettegrew JW, Klunk WE, Panchalingam K, Kanfer JN, McClure RJ. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. *Neurobiol Aging*. 1995; 16:1–4. [PubMed: 7723928]
71. Spagnoli A, Lucca U, Menasce G, Bandera L, Cizza G, Forloni G, Tettamanti M, Frattura L, Tiraboschi P, Comelli M, Senin U, Longo A, Petrini A, Brambilla G, Belloni A, Negri C, Cavazzuti F, Salsi A, Calogero P, Parma E, Stramba-Badiale M, Vitali S, Andreoni G, Inzoli MR, Santus G, Caregnato R, Peruzza M, Favaretto M, Bozeglav C, Alberoni M, De Leo D, Serraiotto L, Baiocchi A, Scoccia S, Culotta P, Ieracitano D. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. *Neurology*. 1991; 41:1726–1732. [PubMed: 1944900]
72. Bonavita E. Study of the efficacy, tolerability of L-acetylcarnitine therapy in the senile brain. *Int J Clin Pharm, Ther & Toxicol*. 1986; 24:511–516.
73. Thal LJ, Calvani M, Amato A, Carta A. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. *Neurology*. 2000; 55:805–810. [PubMed: 10994000]
74. Brooks JO 3rd, Yesavage JA, Carta A, Bravi D. Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. *Int Psychogeriatr*. 1998; 10:193–203. [PubMed: 9677506]
75. Thal LJ, Carta A, Clarke WR, Ferris SH, Friedland RP, Petersen RC, Pettegrew JW, Pfeiffer E, Raskind MA, Sano M, Tuszynski MH, Woolson RF. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. *Neurology*. 1996; 47:705–711. [PubMed: 8797468]
76. Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. *Int Clin Psychopharmacol*. 2003; 18:61–71. [PubMed: 12598816]
77. Bianchetti A, Rozzini R, Trabucchi M. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. *Curr Med Res Opin*. 2003; 19:350–353. [PubMed: 12841930]
78. Hager K, Marahrens A, Kenklies M, Riederer P, Munch G. Alpha-lipoic acid as a new treatment option for Alzheimer type dementia. *Arch Gerontol Geriatr*. 2001; 32:275–282. [PubMed: 11395173]
79. Hager K, Kenklies M, McAfoose J, Engel J, Munch G. Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis. *J Neural Transm Suppl*. 2007:189–193. [PubMed: 17982894]
80. Kamat CD, Gadal S, Mhatre M, Williamson KS, Pye QN, Hensley K. Antioxidants in central nervous system diseases: preclinical promise and translational challenges. *J Alzheimers Dis*. 2008; 15:473–493. [PubMed: 18997301]
81. Pratico D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. *Ann N Y Acad Sci*. 2008; 1147:70–78. [PubMed: 19076432]
82. Bickford PC, Gould T, Briederick L, Chadman K, Pollock A, Young D, Shukitt-Hale B, Joseph J. Antioxidant-rich diets improve cerebellar physiology and motor learning in aged rats. *Brain Res*. 2000; 866:211–217. [PubMed: 10825496]

83. Joseph JA, Denisova N, Villalobos-Molina R, Erat S, Strain J. Oxidative stress and age-related neuronal deficits. *Molecular and Chemical Neuropathology*. 1996; 28:35–40. [PubMed: 8871939]
84. Joseph JA, Denisova NA, Bielinski D, Fisher DR, Shukitt-Hale B. Oxidative stress protection and vulnerability in aging: putative nutritional implications for intervention. *Mech Ageing Dev*. 2000; 116:141–153. [PubMed: 10996014]
85. Lau FC, Shukitt-Hale B, Joseph JA. The beneficial effects of fruit polyphenols on brain aging. *Neurobiol Aging*. 2005; 26(Suppl 1):128–132. [PubMed: 16194581]
86. Cole GM, Morihara T, Lim GP, Yang F, Begum A, Frautschy SA. NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models. *Ann N Y Acad Sci*. 2004; 1035:68–84. [PubMed: 15681801]
87. Crouch PJ, Cimdins K, Duce JA, Bush AI, Trounce IA. Mitochondria in aging and Alzheimer's disease. *Rejuvenation Res*. 2007; 10:349–357. [PubMed: 17708691]
88. Hensley K, Barnes LL, Christov A, Tangney C, Honer WG, Schneider JA, Bennett DA, Morris MC. Analysis of Postmortem Ventricular Cerebrospinal Fluid from Patients with and without Dementia Indicates Association of Vitamin E with Neuritic Plaques and Specific Measures of Cognitive Performance. *J Alzheimers Dis*. 2011; 24:767–774. [PubMed: 21321395]
89. Morris MC, Tangney CC. A potential design flaw of randomized trials of vitamin supplements. *JAMA*. 2011; 305:1348–1349. [PubMed: 21467288]
90. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton C, Welsh-Bohmer KA, Breitner JC. CCS Group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. *Arch Neurol*. 2004; 61:82–88. [PubMed: 14732624]
91. Barberger-Gateau P, Raffaitin C, Letenneur L, Berr C, Tzourio C, Dartigues JF, Alperovitch A. Dietary patterns and risk of dementia: the Three-City cohort study. *Neurology*. 2007; 69:1921–1930. [PubMed: 17998483]
92. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, Wilson RS, Scherr PA. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. *Jama*. 2002; 287:3230–3237. [PubMed: 12076219]
93. Chandra RK. Effect of vitamin and trace-element supplementation on cognitive function in elderly subjects. *Nutrition*. 2001; 17:709–712. [PubMed: 11527656]
94. Williams, JW.; Plassman, BL.; Burke, J.; Holsinger, T.; Benjamin, S. AHRQ Publication No 10-E005. Agency for Healthcare Research and Quality; Rockville, MD: 2010. Alzheimer's Disease and Cognitive Decline. Evidence Report/Technology Assessment No. 193 (Prepared by the Duke Evidence Preventing-based Practice Center under Contract No. HHS 290-2007-10066-I).
95. Shen L, Ji HF. Insights into the disappointing clinical trials of antioxidants in neurodegenerative diseases. *J Alzheimers Dis*. 19:1141–1142. [PubMed: 20308779]
96. Cotman CW, Head E. The canine (dog) model of human aging, disease: dietary, environmental and immunotherapy approaches. *J Alzheimers Dis*. 2008; 15:685–707. [PubMed: 19096165]
97. Head E, Liu J, Hagen TM, Muggenburg BA, Milgram NW, Ames BN, Cotman CW. Oxidative Damage Increases with Age in a Canine Model of Human Brain Aging. *Journal of Neurochemistry*. 2002; 82:375–381. [PubMed: 12124438]
98. Skoumalova A, Rofina J, Schwippelova Z, Gruys E, Wilhelm J. The role of free radicals in canine counterpart of senile dementia of the Alzheimer type. *Exp Gerontol*. 2003; 38:711–719. [PubMed: 12814808]
99. Kiatipattanasakul W, Nakamura S, Kuroki K, Nakayama H, Doi K. Immunohistochemical detection of anti-oxidative stress enzymes in the dog brain. *Neuropathology*. 1997; 17:307–312.
100. Opii WO, Joshi G, Head E, Milgram NW, Muggenburg BA, Klein JB, Pierce WM, Cotman CW, Butterfield DA. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease. *Neurobiol Aging*. 2008; 29:51–70. [PubMed: 17055614]
101. Hwang IK, Yoon YS, Yoo KY, Li H, Choi JH, Kim DW, Yi SS, Seong JK, Lee IS, Won MH. Differences in Lipid Peroxidation and Cu,Zn-Superoxide Dismutase in the Hippocampal CA1 Region Between Adult and Aged Dogs. *J Vet Med Sci*. 2008; 70:273–277. [PubMed: 18388427]

102. Papaioannou N, Tooten PCJ, van Ederen AM, Bohl JRE, Rofina J, Tsangaris T, Gruys E. Immunohistochemical investigation of the brain of aged dogs, Detection of neurofibrillary tangles I, of 4-hydroxynonenal protein, an oxidative damage product, in senile plaques. *Amyloid: J Protein Folding Disord.* 2001; 8:11–21.
103. Rofina JE, Singh K, Skoumalova-Vesela A, van Ederen AM, van Asten AJ, Wilhelm J, Gruys E. Histochemical accumulation of oxidative damage products is associated with Alzheimer-like pathology in the canine. *Amyloid.* 2004; 11:90–100. [PubMed: 15478464]
104. Rofina JE, van Ederen AM, Toussaint MJ, Secreve M, van der Spek A, van der Meer I, Van Eerdenburg FJ, Gruys E. Cognitive disturbances in old dogs suffering from the canine counterpart of Alzheimer's disease. *Brain Res.* 2006; 1069:216–226. [PubMed: 16423332]
105. Cotman CW, Head E, Muggenburg BA, Zicker S, Milgram NW. Brain Aging in the Canine: A Diet Enriched in Antioxidants Reduces Cognitive Dysfunction. *Neurobiology of Aging.* 2002; 23:809–818. [PubMed: 12392784]
106. Milgram NW, Zicker SC, Head E, Muggenburg BA, Murphey H, Ikeda-Douglas CJ, Cotman CW. Dietary enrichment counteracts age-associated cognitive dysfunction in canines. *Neurobiol Aging.* 2002; 23:737–745. [PubMed: 12392778]
107. Milgram NW, Head E, Zicker SC, Ikeda-Douglas C, Murphey H, Muggenburg BA, Siwak CT, Dwight TappP, Lowry SR, Cotman CW. Long-term treatment with antioxidants and a program of behavioral enrichment reduces age-dependent impairment in discrimination and reversal learning in beagle dogs. *Exp Gerontol.* 2004; 39:753–765. [PubMed: 15130670]
108. Milgram NW, Head E, Zicker SC, Ikeda-Douglas CJ, Murphey H, Muggenburg B, Siwak C, Tapp D, Cotman CW. Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study. *Neurobiol Aging.* 2005; 26:77–90. [PubMed: 15585348]
109. Nippak PM, Mendelson J, Muggenburg B, Milgram NW. Enhanced spatial ability in aged dogs following dietary and behavioural enrichment. *Neurobiol Learn Mem.* 2007; 87:610–623. [PubMed: 17303448]
110. Zicker SC. Cognitive and behavioral assessment in dogs and pet food market applications. *Prog Neuropsychopharmacol Biol Psychiatry.* 2005; 29:455–459. [PubMed: 15795054]
111. Milgram NW, Head E, Muggenburg BA, Holowachuk D, Murphey H, Estrada J, Ikeda-Douglas CJ, Zicker SC, Cotman CW. Landmark discrimination learning in the dog: effects of age, an antioxidant fortified diet, and cognitive strategy. *Neuroscience and Biobehavioral Reviews.* 2002; 26:679–695. [PubMed: 12479842]
112. Siwak CT, Tapp PD, Head E, Zicker SC, Murphey HL, Muggenburg BA, Ikeda-Douglas CJ, Cotman CW, Milgram NW. Chronic antioxidant and mitochondrial cofactor administration improves discrimination learning in aged but not young dogs. *Prog Neuropsychopharmacol Biol Psychiatry.* 2005; 29:461–469. [PubMed: 15795055]
113. Calabrese V, Cornelius C, Stella AM, Calabrese EJ. Cellular stress responses, mitostress and carnitine insufficiencies as critical determinants in aging and neurodegenerative disorders: role of hormesis and vitagenes. *Neurochem Res.* 2010; 35:1880–1915. [PubMed: 21080068]
114. Calabrese V, Cornelius C, Dinkova-Kostova AT, Calabrese EJ, Mattson MP. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. *Antioxid Redox Signal.* 2010; 13:1763–1811. [PubMed: 20446769]
115. Head E, Nukala VN, Fenoglio KA, Muggenburg BA, Cotman CW, Sullivan PG. Effects of age, dietary, and behavioral enrichment on brain mitochondria in a canine model of human aging. *Exp Neurol.* 2009
116. Siwak-Tapp CT, Head E, Muggenburg BA, Milgram NW, Cotman CW. Region specific neuron loss in the aged canine hippocampus is reduced by enrichment. *Neurobiol Aging.* 2008; 29:39–50. [PubMed: 17092609]
117. Fahnstock M, Marchese M, Head E, Pop V, Michalski B, Milgram WN, Cotman CW. BDNF increases with behavioral enrichment and an antioxidant diet in the aged dog. *Neurobiol Aging.* 2010
118. Le T, Keithley EM. Effects of antioxidants on the aging inner ear. *Hear Res.* 2007; 226:194–202. [PubMed: 16843623]

119. Christie LA, Opii WO, Head E, Araujo JA, de Rivera C, Milgram NW, Cotman CW. Short-term supplementation with acetyl-L-carnitine and lipoic acid alters plasma protein carbonyl levels but does not improve cognition in aged beagles. *Exp Gerontol.* 2009; 44:752–759. [PubMed: 19735717]
120. Araujo JA, Landsberg GM, Milgram NW, Miolo A. Improvement of short-term memory performance in aged beagles by a nutraceutical supplement containing phosphatidylserine, Ginkgo biloba, vitamin E, and pyridoxine. *Can Vet J.* 2008; 49:379–385. [PubMed: 18481547]

### Highlights

- Oxidative damage increases with brain aging
- Aged dogs naturally develop cognitive decline and brain pathology
- Antioxidants improve cognition and reduce neuropathology in aging dogs  
Antioxidants may be beneficial for human brain aging and Alzheimer's disease